Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 7, 2022; 28(37): 5403-5419
Published online Oct 7, 2022. doi: 10.3748/wjg.v28.i37.5403
Table 2 Overview of Immunotherapy-based novel nanoparticles in the treatment of hepatocellular carcinoma [PubMed Search (immunotherapy) AND (nanoparticle) AND (hepatocellular carcinoma)]
Type of nanoparticle
Treatment strategy
Drugs or active substance involved
The main involvement of immune cells
Ref.
Nano-micellesICD, chemotherapy, PDTPTX, TPABDTOCTLs, MDSCs, Tregs, DCsXu et al[75]
Polymersp53 gene reprograms the immune microenvironmentp53 mRNAT cells, NK cellsXiao et al[83]
MSNPsAnti-angiogenic drugs, ICIsSorafenib, PD-L1 antibodyT cellsLi et al[84]
CopolymersICD, chemotherapyIcaritin, DOXT cells, DCsYu et al[85]
Lipid nanoparticleCCL2 and CCL5 dual-targetBisCCL2/5i mRNATAMsWang et al[87]
MicrocapsulesImproving hypoxiaOxygenTAMsDai et al[91]
CopolymersMitigates LSEC capillarizationSimvastatinNKT cellsYu et al[93]
LNPsAntigen specific vaccineTumor-derived RNAT cells, DCsZhang et al[98]